| Literature DB >> 30568673 |
Alexandre A Lussier1,2, Tamara S Bodnar1, Matthew Mingay3, Alexandre M Morin2, Martin Hirst3,4, Michael S Kobor2,5, Joanne Weinberg1.
Abstract
Background: Prenatal alcohol exposure (PAE) can alter the development of neurobiological systems, leading to lasting neuroendocrine, neuroimmune, and neurobehavioral deficits. Although the etiology of this reprogramming remains unknown, emerging evidence suggests DNA methylation as a potential mediator and biomarker for the effects of PAE due to its responsiveness to environmental cues and relative stability over time. Here, we utilized a rat model of PAE to examine the DNA methylation profiles of rat hypothalami and leukocytes at four time points during early development to assess the genome-wide impact of PAE on the epigenome and identify potential biomarkers of PAE. Our model of PAE resulted in blood alcohol levels of ~80-150 mg/dl throughout the equivalent of the first two trimesters of human pregnancy. Hypothalami were analyzed on postnatal days (P) 1, 8, 15, 22 and leukocytes at P22 to compare central and peripheral markers. Genome-wide DNA methylation analysis was performed by methylated DNA immunoprecipitation followed by next-generation sequencing.Entities:
Keywords: DNA methylation; brain; development; epigenetics; fetal alcohol spectrum disorder; immune; prenatal alcohol exposure
Year: 2018 PMID: 30568673 PMCID: PMC6290329 DOI: 10.3389/fgene.2018.00610
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Overview of the experimental design. We collected the hypothalamus of female offspring from one of three prenatal treatment groups on postnatal days (P) 1, 8, 15, and 22. In parallel, white blood cells were collected on P22 from the same animals as the hypothalamus samples. Each group/age/tissue was composed of four samples for DNA methylation analysis by methylated DNA immunoprecipitated and next-generation sequencing (meDIP-seq).
Figure 2PAE-specific DMRs across pre-weaning development of the hypothalamus. (A) Contrast analysis revealed 118 PAE-specific differentially methylated regions (DMR), which were significantly different in PAE vs. C animals and PAE vs. PF animals, but not significantly different between PF vs. C. (B) The DMRs showed consistent difference between PAE animals and controls across ages. Each row represents a different DMR, while each column shows the mean for all animals within that group/age (n = 4). Reads per kilobase per million (RPKM) data were scaled and centered to produce a Z-score for each DMR, where those in blue showed less DNA methylation enrichment and those in red showed more enrichment.
Figure 3Enrichment patterns of the developmental DMRs. (A) Genomic feature enrichment profile of all, up-methylated, and down-methylated DMRs. The probe counts for each feature (blue) were compared to the results from permutation analyses of 118 random regions (orange), which were used to compute the p-value. The majority of DMRs were located in intergenic regions or introns. Up-methylated regions in PAE animals contained more CpG islands (CGI) and exons than expected by chance (p < 0.05). (B) Overrepresentation analysis of transcription factor binding sites in the DMRs. Only BHLHE40 showed higher enrichment in the PAE-specific DMRs (blue) than by random chance (orange; p < 0.05), although SREBF1 and MLX trended toward significance (p < 0.1). *p < 0.05, #p < 0.1.
Biological processes enriched in the developmental profile DMRs.
| Glucocorticoid receptor signaling pathway | 0042921 | 4 | 0.475 | 0.00117 | 0.00432 | 0.06853 | 0.0011 | 0.00456 | 0.07096 |
| Intracellular steroid hormone receptor signaling pathway | 0030518 | 27 | 0.681 | 0.00146 | 0.00865 | 0.09115 | 0.00148 | 0.00765 | 0.09009 |
| Corticosteroid receptor signaling pathway | 0031958 | 5 | 0.442 | 0.0025 | 0.01919 | 0.10193 | 0.00269 | 0.01955 | 0.1019 |
| Regulation of myeloid dendritic cell activation | 0030885 | 2 | 0.129 | 0.00816 | 0.0198 | 0.14194 | 0.00843 | 0.01869 | 0.14077 |
| Negative regulation of myeloid dendritic cell activation | 0030886 | 2 | 0.129 | 0.00816 | 0.02063 | 0.1637 | 0.00843 | 0.01978 | 0.163 |
| Histone demethylation | 0016577 | 13 | 0.397 | 0.01224 | 0.02727 | 0.18051 | 0.01204 | 0.02756 | 0.17928 |
| Protein demethylation | 0006482 | 15 | 0.365 | 0.01636 | 0.0284 | 0.18496 | 0.01597 | 0.02785 | 0.18571 |
| Protein dealkylation | 0008214 | 15 | 0.365 | 0.01636 | 0.02926 | 0.2578 | 0.01597 | 0.02805 | 0.26243 |
| Calcium ion export | 1901660 | 3 | 0.345 | 0.0166 | 0.02927 | 0.32371 | 0.01739 | 0.02926 | 0.32667 |
| Protein sumoylation | 0016925 | 11 | 0.328 | 0.01845 | 0.03449 | 0.33119 | 0.01688 | 0.03389 | 0.33539 |
| Regulation of protein targeting to membrane | 0090313 | 11 | 0.631 | 0.01845 | 0.03449 | 0.42205 | 0.01688 | 0.03389 | 0.42409 |
| Intracellular estrogen receptor signaling pathway | 0030520 | 6 | 0.523 | 0.01891 | 0.0354 | 0.42205 | 0.01913 | 0.0354 | 0.42409 |
| Histone H3 deacetylation | 0070932 | 8 | 0.419 | 0.02819 | 0.04091 | 0.56227 | 0.03028 | 0.04161 | 0.56796 |
| Relaxation of smooth muscle | 0044557 | 6 | 0.679 | 0.03185 | 0.04117 | 0.56279 | 0.03219 | 0.04121 | 0.56348 |
| Midbrain-hindbrain boundary development | 0030917 | 3 | 0.267 | 0.03285 | 0.04178 | 0.72697 | 0.03382 | 0.04319 | 0.72413 |
| GDP-mannose metabolic process | 0019673 | 5 | 0.252 | 0.03451 | 0.04275 | 0.7401 | 0.03368 | 0.04445 | 0.73884 |
| Protein deacetylation | 0006476 | 20 | 0.664 | 0.04114 | 0.04456 | 0.76723 | 0.04009 | 0.04284 | 0.76878 |
| Regulation of acyl-CoA biosynthetic process | 0050812 | 4 | 0.358 | 0.04459 | 0.04469 | 0.89405 | 0.04633 | 0.04556 | 0.89682 |
| Germinal center B cell differentiation | 0002314 | 2 | 0.073 | 0.0467 | 0.04469 | 0.89405 | 0.04618 | 0.04556 | 0.89682 |
| Negative regulation of nuclear division | 0051784 | 24 | 0.774 | 0.04736 | 0.04683 | 0.97779 | 0.04927 | 0.04737 | 0.97771 |
Figure 4Bisulfite pyrosequencing verification of the Drd4 DMR. 16 CpGs (#7–22) spanning 380 base pairs (bp) of the DMR located in the 3′ UTR of Drd4 were verified by pyrosequencing in the same animals as the meDIP-seq analysis. All CpGs on P1 displayed >5% change in DNA methylation levels between PAE (red) and controls (blue). Of these, several were consistently different across all ages and a number persisted until P22. The total levels of DNA methylation in the DMR also increased with age across all groups.
Summary of the pyrosequencing results for the Drd4 DMR.
| All ages | 44.310 | 40.211 | 3.925 | 1.549 | 6.301 | 1.212 | 2.59E-03 | CpG 7–22 | CpG 7, 9, 10, 17, 18 | CpG 7, 9, 10, 17, 18 |
| P1 | 32.868 | 27.748 | 5.120 | 2.371 | 7.869 | 1.402 | 6.49E-03 | CpG 7–21 | CpG 7, 9, 10, 15–17 | CpG 7, 9, 10, 15–17 |
| P8 | 41.393 | 41.666 | −0.273 | −5.214 | 4.667 | 2.521 | 9.16E-01 | CpG 7 | CpG 7 | CpG 7 |
| P15 | 49.393 | 44.790 | 4.603 | 2.120 | 7.085 | 1.267 | 8.36E-03 | CpG 7–10, 12, 13, 15–17 | CpG 7, 10, 13, 16 | CpG 7, 10, 13, 16 |
| P22 | 53.587 | 47.555 | 6.032 | 1.452 | 10.613 | 2.337 | 3.25E-02 | CpG 8, 13, 16–20 | CpG 8–11, 13, 15, 17–22 | CpG 8, 13, 17–20 |
Figure 5PAE-specific DMRs concordant across the hypothalamus and white blood cells. (A) Contrast analysis revealed 299 PAE-specific differentially methylated regions (DMR) between both tissues, which were significantly different in PAE vs. C animals and PAE vs. PF animals, but not significantly different between PF vs. C. (B) Heatmap of the DMRs. Each row represents a different DMR, while each column shows the meDIP-seq data for each animal (n = 4, except PF WBC: n = 3). Reads per kilobase per million (RPKM) data were scaled and centered to produce a Z-score for each DMR, where those in blue showed less DNA methylation enrichment and those in red showed more enrichment. PAE-specific DMRs showed the same direction of change in both tissues, with some graded effects of tissue type.
Figure 6Enrichment patterns of the tissue-concordant DMRs. (A) Genomic feature enrichment profile of all, up-methylated, and down-methylated DMRs. The probe counts for each feature (blue) were compared to the results from permutation analyses of 299 random regions (orange), which were used to compute the p-value. While the majority of DMRs were located in intergenic regions, they showed a higher proportion than expected by random change (p < 0.01). By contrast, exon/intron boundaries were underrepresented in the DMRs, particularly within the regions that were down-methylated in PAE animals. (B) Overrepresentation analysis of transcription factor binding sites in the DMRs. Several TFBS showed higher enrichment in the tissue-concordant DMRs (blue) than expected by random chance (orange), with GMEB1 showing the highest enrichment at 16% of all DMRs. *p < 0.05, **p < 0.01.
Biological processes enriched in the tissue-concordant DMRs.
| Cellular aldehyde metabolic process | 6081 | 29 | 0.785 | 0.00089 | 0.00081 | 0.0531 | 0.00094 | 0.00093 | 0.05423 |
| T-helper 1 cell differentiation | 45063 | 5 | 0.483 | 0.0026 | 0.00284 | 0.0531 | 0.00261 | 0.00319 | 0.05423 |
| Amino-acid betaine metabolic process | 6577 | 10 | 0.484 | 0.00275 | 0.00383 | 0.05739 | 0.0028 | 0.0034 | 0.058 |
| Carnitine metabolic process | 9437 | 7 | 0.36 | 0.00284 | 0.00414 | 0.06279 | 0.00321 | 0.00391 | 0.06181 |
| Osteoblast fate commitment | 2051 | 2 | 0.224 | 0.0044 | 0.00465 | 0.09845 | 0.00413 | 0.00434 | 0.09938 |
| Plasma membrane repair | 1778 | 7 | 0.109 | 0.00599 | 0.0051 | 0.1162 | 0.00631 | 0.00474 | 0.11789 |
| Negative regulation of circadian sleep/wake cycle, REM sleep | 42322 | 2 | 0.324 | 0.00788 | 0.0051 | 0.14968 | 0.00829 | 0.00474 | 0.15006 |
| Chromatin remodeling | 6338 | 43 | 0.753 | 0.01171 | 0.00597 | 0.17051 | 0.01135 | 0.00569 | 0.17029 |
| Negative regulation of axon regeneration | 48681 | 3 | 0.41 | 0.01139 | 0.0092 | 0.17521 | 0.01204 | 0.00896 | 0.17422 |
| Regulation of natural killer cell cytokine production | 2727 | 2 | 0.293 | 0.01217 | 0.01155 | 0.17521 | 0.01348 | 0.01048 | 0.17422 |
| Positive regulation of natural killer cell cytokine production | 2729 | 2 | 0.293 | 0.01217 | 0.01082 | 0.22896 | 0.01348 | 0.01057 | 0.2317 |
| Amino-acid betaine biosynthetic process | 6578 | 5 | 0.219 | 0.01428 | 0.01082 | 0.25627 | 0.01367 | 0.01057 | 0.25577 |
| Glucose 1-phosphate metabolic process | 19255 | 2 | 0.0827 | 0.01405 | 0.0106 | 0.29844 | 0.01546 | 0.01064 | 0.30042 |
| Cellular response to interleukin-18 | 71351 | 2 | 0.23 | 0.01587 | 0.0114 | 0.31438 | 0.01748 | 0.01094 | 0.317 |
| Protein K63-linked deubiquitination | 70536 | 12 | 0.126 | 0.02072 | 0.01396 | 0.33657 | 0.02115 | 0.01351 | 0.33588 |
| Carnitine biosynthetic process | 45329 | 3 | 0.085 | 0.02242 | 0.01864 | 0.34572 | 0.02301 | 0.02005 | 0.34264 |
| Positive regulation of interleukin-10 production | 32733 | 15 | 0.81 | 0.02457 | 0.02429 | 0.34572 | 0.02509 | 0.02327 | 0.34264 |
| Response to jasmonic acid | 9753 | 3 | 0.405 | 0.02597 | 0.02429 | 0.37241 | 0.02675 | 0.02327 | 0.36841 |
| Cellular response to jasmonic acid stimulus | 71395 | 3 | 0.405 | 0.02597 | 0.02776 | 0.38417 | 0.02675 | 0.02755 | 0.38807 |
| Response to interleukin-18 | 70673 | 3 | 0.404 | 0.02741 | 0.03021 | 0.44431 | 0.02814 | 0.02905 | 0.44259 |
| Cofactor catabolic process | 51187 | 13 | 0.638 | 0.0291 | 0.03294 | 0.44477 | 0.02836 | 0.03162 | 0.44499 |
| Extracellular polysaccharide biosynthetic process | 45226 | 2 | 0.12 | 0.02809 | 0.03374 | 0.50515 | 0.02987 | 0.03253 | 0.50571 |
| Extracellular polysaccharide metabolic process | 46379 | 2 | 0.12 | 0.02809 | 0.03382 | 0.53397 | 0.02987 | 0.03259 | 0.53274 |
| Acetaldehyde metabolic process | 6117 | 2 | 0.216 | 0.03048 | 0.03547 | 0.53397 | 0.03224 | 0.03553 | 0.53274 |
| Protein K48-linked deubiquitination | 71108 | 12 | 0.0357 | 0.0314 | 0.03784 | 0.58202 | 0.03277 | 0.03703 | 0.57955 |
| Cellular response to light stimulus | 71482 | 38 | 0.821 | 0.03665 | 0.03755 | 0.58809 | 0.03621 | 0.03751 | 0.58519 |
| Podosome assembly | 71800 | 3 | 0.0518 | 0.03607 | 0.03755 | 0.61294 | 0.03643 | 0.03751 | 0.61412 |
| Micturition | 60073 | 5 | 0.536 | 0.04093 | 0.03865 | 0.65836 | 0.03964 | 0.0376 | 0.65844 |
| Regulation of histone H4 acetylation | 90239 | 5 | 0.465 | 0.04093 | 0.03969 | 0.66132 | 0.03964 | 0.03965 | 0.66174 |
| Adenylate cyclase-activating G-protein coupled receptor signaling pathway | 7189 | 26 | 0.73 | 0.038 | 0.04176 | 0.7519 | 0.03969 | 0.04102 | 0.75163 |
| ER to Golgi ceramide transport | 35621 | 2 | 0.11 | 0.03821 | 0.04171 | 0.76157 | 0.03982 | 0.04149 | 0.75818 |
| Ceramide transport | 35627 | 2 | 0.109 | 0.03821 | 0.04174 | 0.81677 | 0.03982 | 0.04231 | 0.81613 |
| Glycolipid transport | 46836 | 2 | 0.0288 | 0.03821 | 0.04318 | 0.84505 | 0.03982 | 0.0426 | 0.84661 |
| Regulation of circadian sleep/wake cycle, REM sleep | 42320 | 4 | 0.439 | 0.04575 | 0.04318 | 0.86337 | 0.04542 | 0.0426 | 0.86292 |
| Negative regulation of acute inflammatory response | 2674 | 6 | 0.674 | 0.04567 | 0.04881 | 0.94037 | 0.04575 | 0.04964 | 0.93962 |